Clinical Trials Sponsored by Byron Lam

Total 8587 results

Hoffmann-La Roche

Recruiting

Study of Zifibancimig in Participants With Neovascular Age-Related Macular Degeneration (BURGUNDY)

Macular Degeneration

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

Multiple Myeloma

Belgium, Korea, Republic of, Denmark, United Kingdom, Australia, New Zealand, Italy, Spain, France
Hoffmann-La Roche

Recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

Korea, Republic of, United States, China, Germany, Poland, Spain, Taiwan, United Kingdom, Australia, France, Belgium, Switzerland, Denmark, Puerto Rico
Hoffmann-La Roche

Recruiting

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Neoplasms

Italy, France, Turkey, Korea, Republic of, Spain, China, United States, Hong Kong, Russian Federation, Poland
Hoffmann-La Roche

Active, not recruiting

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, Belgium, France, Italy, Spain, Brazil, Australia, Germany, Turkey, Mexico, United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (FeDeriCa)

Early Breast Cancer

France, Spain, United States, Korea, Republic of, Canada, United Kingdom, Argentina, Belgium, Germany, Italy, Taiwan, Thailand, Japan, Mexico, Brazil, Czechia, Poland, Russian Federation, Ukraine
Hoffmann-La Roche

Active, not recruiting

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)

Solid Tumors | CNS Tumors

United States, Spain, Korea, Republic of, Canada, Germany, United Kingdom, China, Italy, Hong Kong, France, Taiwan
Hoffmann-La Roche

Active, not recruiting

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

Chronic Lymphocytic Leukemia (CLL)

United States, Italy, Australia, Spain, France
Hoffmann-La Roche

Active, not recruiting

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) (FENopta)

Relapsing Multiple Sclerosis

Czechia, Serbia, United States, Croatia, Bosnia and Herzegovina, Slovakia
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder

United States, Spain, United Kingdom, Taiwan, Hungary, Korea, Republic of, Japan, Croatia, Bulgaria, Canada, Germany, Italy, Poland, Puerto Rico, Romania, Turkey, Ukraine, Malaysia
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251)

Unresectable Hepatocellular Carcinoma

Canada, Belgium, Korea, Republic of, Brazil, China, Croatia, Spain, Taiwan, Turkey, Italy, India, United Kingdom, Thailand, Costa Rica, Japan, France, Germany, Austria, Israel, Malaysia, Philippines, Estonia, Russian Federation, Greece, Bulgari... and more
Hoffmann-La Roche

Active, not recruiting

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Korea, Republic of, Argentina, Denmark, France, Spain, Brazil, United Kingdom, Turkey, Czechia, Thailand, Russian Federation, Italy, Poland, Taiwan, Singapore, Ukraine, Kenya, Hungary
Hoffmann-La Roche

Active, not recruiting

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

HER2-positive Early Breast Cancer

China
Hoffmann-La Roche

Completed

Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) (URBAN)

Follicular Lymphoma

Italy
Hoffmann-La Roche

Completed

A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Carcinoma, Thymic

China
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance)

Relapsing Multiple Sclerosis

United States, Mexico, Hungary, China, Germany, Italy, Peru, Poland, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Tunisia, Netherlands, Argentina, Georgia, Hong Kong, Kenya, Dominican Republic, Finland, North Macedonia, Serb...
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)

Progressive Multiple Sclerosis (PMS)

United States, Canada, Brazil, France, Netherlands, Ireland, Germany, Italy, Poland, Russian Federation, Spain, Colombia, Morocco, Hungary, Denmark, Lebanon, Mexico, Costa Rica, Bosnia and Herzegovina, Czechia, Egypt, Guatemala, Panama and more
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)

Diabetic Macular Edema

United States, Korea, Republic of, United Kingdom, Brazil, China, Canada, Argentina, Australia, Denmark, France, Italy, Poland, Spain, Germany, Singapore, Czechia, Hong Kong, Portugal, Russian Federation, Taiwan, Hungary, Switzerland and more
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition (COMMODORE 3)

Paroxysmal Nocturnal Hemoglobinuria

China
Hoffmann-La Roche

Active, not recruiting

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Metastatic Melanoma | Non-small Cell Lung Cancer (NSCLC) | Solid Tumors | Esophageal Squamous Cell Carcinoma (ESCC) | Small Cell Lung Cancer (SCLC)

United States, Korea, Republic of, Denmark, France, Spain, New Zealand
Hoffmann-La Roche

Active, not recruiting

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung)

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, France, Israel, Taiwan, Australia, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Canada, Brazil, Korea, Republic of, Spain, Argentina, United States, Costa Rica, Chile, Latvia, Finland, Italy, Poland
Hoffmann-La Roche

Active, not recruiting

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Non-Small Cell Lung Cancer

United States, Spain, Italy, Taiwan, Belgium, China, Hong Kong, Japan, Germany, Canada, Israel, Russian Federation, United Kingdom, France, Korea, Republic of, Poland, Netherlands, Ukraine, Romania, Australia, Hungary, Portugal
Hoffmann-La Roche

Active, not recruiting

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis (MuSicalE)

Multiple Sclerosis

Belgium, United Kingdom, Netherlands, Serbia, Poland, Slovakia, Bulgaria, Turkey, Brazil, Italy, Russian Federation, Spain, Austria, Colombia, Romania, Kuwait, Chile, Dominican Republic, Egypt, Montenegro, Panama, Paraguay, Portugal, ... and more
Hoffmann-La Roche

Active, not recruiting

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Cancer

United States, Canada, France, Italy, Slovenia, Spain, Turkey, United Kingdom, Argentina, Brazil, Poland, Australia, Czechia, Thailand, Korea, Republic of, Russian Federation, Switzerland, Japan, Taiwan, Austria, Belgium, Portugal, ... and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR)

Severe Hemophilia A | Moderate Hemophilia A

Brazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma (SKYSCRAPER-08)

Esophageal Cancer

Korea, Republic of, China, Hong Kong, Thailand, Taiwan
Hoffmann-La Roche

Active, not recruiting

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Diabetic Macular Edema

United States, United Kingdom, Korea, Republic of, Argentina, Poland, Puerto Rico, Czechia, Spain, Canada
Hoffmann-La Roche

Completed

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (MODUL)

Colorectal Cancer

Italy, Korea, Republic of, United Kingdom, Belgium, Argentina, Denmark, Greece, Netherlands, Slovenia, Spain, Sweden, Turkey, Brazil, Bosnia and Herzegovina, France, Germany, Portugal, Egypt, Poland, Slovakia, Mexico, Serbia, Russian...
Hoffmann-La Roche

Completed

A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

COVID-19

Spain, Germany, United States, Brazil, Italy, France, Greece, Croatia, Poland, South Africa, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Non-Hodgkin Lymphoma | B-Cell Lymphoma

United States, Italy, Canada, Australia, Spain, Denmark, France, Germany, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Non-Small-Cell Lung

United States, Korea, Republic of, United Kingdom, Australia, France, Italy, Spain, Japan, Brazil, China, Germany, Poland, Thailand, Israel, Switzerland, Taiwan, Austria, Russian Federation, Ukraine, Hungary, Serbia, Slovenia, South... and more
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis (STARSCAPE)

Idiopathic Pulmonary Fibrosis

United States, Spain, France, Belgium, Australia, Denmark, Italy, Taiwan, Japan, Singapore, Turkey, Korea, Republic of, Germany, China, Ukraine, New Zealand, Netherlands, United Kingdom, Israel, Finland, Argentina, Czechia, Portugal, South... and more
Hoffmann-La Roche

Active, not recruiting

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

Age-Related Macular Degeneration
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09)

Squamous Cell Carcinoma of Head and Neck

United States, Korea, Republic of, United Kingdom, Czechia, New Zealand, France, Spain, Greece, Thailand, Taiwan, Hungary, Italy, Poland
Hoffmann-La Roche

Active, not recruiting

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3)

Metastatic Breast Cancer

Korea, Republic of, United Kingdom, Australia, China, Croatia, Finland, France, Norway, Portugal, Slovenia, Canada, Italy, Spain, Colombia, Brazil, Poland, United States, Greece, Turkey, Russian Federation, Philippines
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

Inflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Canada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Spain, China, Denmark, Italy, Germany, Mexico, Poland, United States, Brazil, Peru, Thailand, Serbia, Switzerland, Japan, Turkey, Netherlands, Austria, Taiwan, Russian Federation, Ukraine, Greece
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Switzerland, Australia
Hoffmann-La Roche

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Endocrine System Diseases | Gastrointestinal Neoplasms | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Respiratory Tract... and other conditions

France, Spain, United States, Korea, Republic of, United Kingdom, Taiwan, China, Belgium, Singapore, Netherlands, Germany, Italy, Hong Kong
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Urinary Tract Cancer

Hungary, Italy, Australia, Czechia, United Kingdom, Austria, Belgium, Brazil, Bulgaria, Croatia, Denmark, Estonia, Greece, Portugal, Spain, Canada, India, Romania, Switzerland, Poland, Ireland, Colombia, Germany, Argentina, China, Lebanon, ... and more
Hoffmann-La Roche

Completed

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Advanced Follicular Lymphoma

Germany, Brazil, United Kingdom, Spain, Japan, United States, Netherlands
Hoffmann-La Roche

Completed

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)

Triple-Negative Breast Cancer

France, Canada, Israel, Italy, Argentina, Brazil, China, Croatia, Germany, Greece, Slovakia, Turkey, Saudi Arabia, Japan, India, Spain, United States, Czechia, Romania, United Kingdom, Morocco, South Africa, Vietnam, Russian Federation
Hoffmann-La Roche

Completed

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Colorectal Cancer

United States, France, Denmark, Spain
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Multiple Sclerosis

United States, Brazil, Poland, United Kingdom, Turkey, Bulgaria, Belgium, Canada, Denmark, France, Germany, Greece, Hungary, Italy, Peru, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Mexico, Argentina
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Belgium, Czechia, Russian Federation, Serbia, Spain, Italy, Netherlands, Finland, Estonia, Brazil, France, Germany, Poland, Switzerland, Ukraine, Peru, Argentina, Lithuania, Slovakia, Portugal, Australia, Hungary, Tunisia, Bulgar... and more
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Huntingtons Disease

United States, United Kingdom, Australia, Canada, Japan, Poland, Netherlands, Germany, Russian Federation, France, Spain, Argentina, New Zealand, Austria, Denmark, Italy, Switzerland, Chile
Hoffmann-La Roche

Completed

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lymphoma

China
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

Solid Tumors

United States, Spain, Belgium, Denmark, Canada, Australia
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, Hungary, Brazil, Finland, Italy, Germany, Romania, Lithuania, France, Greece, Peru, Portugal, Spain, Switzerland, Bulgaria, Ukraine, Israel, Poland, Austria, New Zealand, Netherlands, Belgium, Mexico, United... and more

Clinical Trials Sponsored by Byron Lam

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations